Several clinical trials have addressed the promising anticancer effect of metformin on the
survival benefits, clinical response, and pathological response of breast cancer patients.
Therefore, this study will assess the anticancer effect of metformin when added to the
neoadjuvant chemotherapy protocol of non-diabetic breast cancer patients. In addition to, the
impact of metformin addition to the neoadjuvant chemotherapy on the quality of life of breast
cancer patients.